Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

Lokelma Has Been Approved in Japan for the Treatment of Patients with Hyperkalaemia

AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) has been approved in Japan for the treatment of patients with hyperkalaemia (elevated levels of potassium in the blood). The approval by Japan...

AstraZeneca to Donate 9 Million Face Masks to Support Healthcare Workers

AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. In addition to these donations, A...

License to RedHill Biopharma Supports AstraZeneca’s Focus on Main Therapy Areas

AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid recepto...

AstraZeneca invest $200m in local manufacturing in Australia

AstraZeneca committed $200m to the company’s manufacturing facility in North Ryde, Sydney. The investment follows $100m announced in 2017 and will go towards increasing the facility’s production capab...

AstraZeneca to Sell Rights to Established Hypertension Medicines

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestore...

AstraZeneca is Investing More in Continental Europe

AstraZeneca just unveiled a $520 million investment in France across the spectrum of manufacturing and R&D. The announcement came as French President Emmanuel Macron wooed business leaders during ...

Lynparza Approved for gBRCAm Metastatic Pancreatic Adenocarcinoma Treatment

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US for the maintenance treatme...

FDA Recommended Lynparza for Metastatic Adenocarcinoma of Pancreas Treatment

AstraZeneca and MSD Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee ...

AstraZeneca Received Marketing Authorisation from NMPA for Imfinzi

china street
AstraZeneca announced that it has received marketing authorisation from China’s National Medical Products Administration (NMPA) for Imfinzi (durvalumab) for the treatment of patients with unrese...

AZ and Daiichi Sankyo Presented “Clinically Meaningful” Responses to Trastuzumab Deruxtecan

AstraZeneca and Daiichi Sankyo have presented new mid-stage data showing “clinically meaningful” responses in patients with advanced breast cancer taking trastuzumab deruxtecan. The pivotal Phase I...

AstraZeneca and Novoheart will Develop First Functional Model of Specific Type of Heart Failure

AstraZeneca has announced a collaboration with biotechnology company Novoheart to develop the world’s first functional model of a specific type of heart failure. The companies will work together to...

AstraZeneca Agreed to Sell Rights to Seroquel and Seroquel XR in the US and Canada

AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzn...

FDA Accepted sBLA and Granted Priority Review for Imfinzi

astrazeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treat...

Jerusalem Venture Partners and AstraZeneca Signed Cooperation Agreement

astrazeneca
Jerusalem Venture Partners and British multinational pharmaceutical company AstraZeneca have signed a cooperation agreement to identify, develop and invest in digital health in Israel, the Jerusalem-b...

FDA Approved New Treatment Option for Patients with Chronic Lymphocytic Leukemia

As part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the U.S. Food and Drug Administration granted supplemental approval to Calquence...

European Commission Approved AstraZeneca Qtrilmet

diabetes
AstraZeneca announced that the European Commission has approved Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets to improve glycaemic control in adults with t...